- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
How BMS is Doing RBM (Risk-Based Monitoring)
At this year’s Bio IT World Conference, Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb,
At this year’s Bio IT World Conference, Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb, elaborated on BMS’s risk-based monitoring (RBM) pilot, and how they are leveraging data, statistical analysis and personnel to execute RBM.
In this Applied Clinical Trials blog, Moe Alsumidale outlines the BMS’s RBM infrastructure.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
